Haystack MRD (DGX)

Executive Summary

Haystack MRD is a US-based diagnostics company pioneering a tumor-informed, next-generation sequencing liquid biopsy test for minimal residual disease (MRD) detection. The company's platform detects circulating tumor DNA (ctDNA) with exceptional sensitivity and specificity, enabling precise monitoring of treatment response and early relapse in cancer patients. By providing clinicians and biopharma partners with actionable insights, Haystack MRD aims to improve clinical outcomes and accelerate therapeutic development. With a valuation of approximately $22 billion, the company is well-capitalized to scale its technology and pursue regulatory approvals. Its focus on MRD testing addresses a critical unmet need in oncology, as sensitive detection of residual disease can guide adjuvant therapy decisions and reduce unnecessary treatments.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance or CLIA validation of MRD test80% success
• Q3 2026Strategic partnership with a top-10 pharmaceutical company for drug development70% success
• Q2 2026Publication of clinical validation data in a peer-reviewed journal90% success